Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.

• Asıl Yazarlar: Aurélie Chauffour (Yazar), Jérôme Robert (Yazar), Nicolas Veziris (Yazar), Alexandra Aubry (Yazar), Kevin Pethe (Yazar), Vincent Jarlier (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Public Library of Science (PLoS), 2020-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimic...